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QpKer. This study was couducRd to test the hypothesis that
toy me inhibition may lessen myocardial
nit patients with microvascular angina.
Bc,v,r,gmxd. Patients with syndrome X (angina
pectoris,
pos-
itive findings on exercise testing and normcnal coronary arterio-
gpmw) have a reduced coronary vasadRalor reserve (11microvas-
cular mighWI) and may dww an increased sympathetic drive .
enzyme inhibition attenuates sympathetic
0womary vawmMexoWnWWWWomn in patients with coronary artery dis-
Mdhods.
Ten patients (seven women and three men, mean age
QMN It * 6 pmrl with syndinnne X sod a mWd1weved coronary flow
reserve underwent a ran6dommsiumd, sinoublind, crossover, place-
Wontrolled study of vie emects of the mqbmuwamvetting
ewyme
	
bitor enalapril on angina and exercise-induced ST
t depression. Assessment was by
symptom-limed
tread-
min exenise testing amw 2 weeks of treatment with 10 mglday of
ensiapril and alter 2 weeks of placebo administration .
Patients with "microvascular angina" (1) or "syndrome X"
(2-4) have exertional angina that appears to be caused by an
abnormal vasodilator capacity of the coronary microcircula-
tion (1,3,5-7) . In these patients, ergonovine can exacerbate
limited coronary flow reserve during pacing in the absence of
epicardial coronary artery spasm (7) . A large proportion of
patients with syndrome X have rest angina and ischemia-like
ST segment depression during ambulatory electrocardio-
graphic (ECG) monitoring that is not always preceded by an
increase in heart rate . Therefore, dynamic small vessel
From the Coronary Artery Disease Research Group. Department of
Card al Sciences. St
. George's Hospital Medical School, London,
England, United Ki*om, This study was presented in abstract form at the
65th Annual Scientific Sessions of the American Heart Association, Novem-
ber 1992
. Dr
. Rosano was sponsored by an Educational Grant from the Italian
Ministry of Health, Rome, Italy and Dr . Gavrielides by an Educational Grant
from the University of Thessaloniki, Thessaloniki, Greece .
Manuscript received July 30 . 1993
; revised manuscript received October
7
. 199-1 ,
accepted October 14, 1993
.
for
mmsnowdkenc : Dr. Juan Carlos Kaski, Coronary Artery
Disease Research Group, Department of Cardiological Sciences, St
. George's
Hospital Medical School, Cranmer Terrace, London SW17 ORE, England
.
United Kingdom.
0 1994 by the American College or Cardiology
MCC Vol. 23, No . 3
March 1, 1994:652-7
Results. Ali patients had positive findings on exercise testing
( :t_- I min ST segment depression and angina) while taking placebo,
whereas six patients had a positive test result (four with angina)
during enalapril therapy. Total exercise duration and time to
I mm of ST segment depression wene prolonged by enWaprill over
those obtained with placebo (mean 779 141 vs . 690 ± 148 s, p =
0.006 and d9O al: 204 vs. 415 cc 241 s, p 0 . 7, respectively) . The
magnitude
of ST segment depression was also less with enalapril
than with placebo (mean 1.1 ± 0.4 vs. I .S ± 0.2 mm, p -- 0.004).
Heart rate and blood pressure at peak exercise and at 1 man of ST
depression were not significantly different during placebo and
enalapril treatment.
Conclusions . Angiotensin-converting enzyme inhibition lessens
exercise-induced ischemia in patients with syndrome X and mi-
crovascular aqlinsl, probably by a direct modulation of coronary
microvascular tone, which results in an increased myocardial
oxygen supply .
(J Am Coll Cardiol 1994,23 :652-7)
constriction has been suggested to play a role in the genesis
of angina in these patients (4)
. Recently, it has been shown
(8) that in patients with microvascular angina the abnormal
vasodilator reactivity affects net only the coronary microcir-
culation but also the systemic vasculature .
Although coronary blood flow is primarily governed by
autoregulatory mechanisms dependent on myocardial oxy-
gen needs, this primacy of local factors does not negate the
fact that neural and humoral influences can play an impor-
tant modulatory role under certain conditions . Studies (9,14)
have shown that the renin-angiotensin system is activated in
patients with ischemic heart disease and myocardial infarc-
tion and that endogenous angiotensin II participates in the
control of coronary blood flow during transient myocardial
ischemia. However, the pathogenetic mechanisms in these
disorders may be different from those causing syndrome X .
Angiotensin-converting enzyme inhibitor drugs increase
coronary blood flow in the presence of an activated renin-
angiotensin system. A potential mechanism of action may be
the blockade of tissue angiotensin generation (11) . More-
over, angiotensin-converting enzyme inhibition reduces left
ventricular diastolic pressure, systolic pressure and sympa-
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thetic drive (12-14), thus reducing myocardial work . These
effects may be beneficial in patients with angina pectoris .
However, the effects of angiotensin-converting enzyme in-
hibition on myocardial ischemia in patients with coronary
artery disease are variable ( 1 5) .
The observations that the syndrome of microvascular
angina is associated with an abnormal dilator response of the
coronary microcirculation and that angiotensin-cone 4rting
enzyme inhibition attenuates sympathetic coronary vaso-
constriction in patients with coronary artery disease
prompted us to examine the effects of angiotensin-
converting enzyme inhibition on the exercise response of
patients with syndrome X .
Methods
Patients. Ten patients (seven women, three men, aged 42
to 65 years, mean age (± SEq 53
4: 6 years) with syndrome X
and microvascular angina were included in the study . Syn-
drome X was definek, as typical exertional angina, a positive
exercise test result (ii- I mm of ST segment depression and
angina), abnormal coronary blood flow reserve and a com-
pletely normal coronary arteriogram . No patient nad left
ventricular hypertrophy . Left ventricular mass index ranged
from 78 to 95 g/m2 in the seven women and from 83 to
122 g/m
2
in the three men . Measurements were obtained
according to American Society of Echocardiography recom-
mendations (16) . Left ventricular wall thickness was calcu-
lated as the arithmetic mean of both posterior and interven-
tricular septal thickness, and left ventricular mass was
calculated using the method proposed by Troy et al . (17) .
Left ventricular hypertrophy was excluded using gender-
specific normal limits from the Framingham Heart Study
(18) . No patient had systemic hypertension (defined as a
blood pressure > 140/90 mm Hg in repeated readings), coro-
nary artery spasm, cardiomyopathy, valvular heart disease
or conduction disturbances . All patients with syndrome X
included in the study had episodes of horizontal or
downsloping ST segment depression during 24-h ambulatory
ECG monitoring, and seven had reversible regional perfu-
sion abnormalities during exercise as assessed by techne-
tium-99m hexamibi scans in five and by positron emission
tomography (rubidium-82) in the remaining two . Coronary
blood flow reserve in response to intravenous dipyridamole,
assessed by positron emission tomography (oxygen-15-
labeled water [19,201) was reduced in all 10 patients (mean
2.3 ± 0.3), as found also by Geltman et al . (21) using a similar
technique .
Study protocol. Ethics . The study protocol was ap-
proved by the hospital's ethics committee . The nature of the
study was explained to each subject before written informed
consent was obtained .
Design . We investigated the effects of enalapril (5 mg
twice daily) in a randomized, single-blind, placebo-
controlled, crossover study wfth two treatment periods of 2
weeks each. The dose of enaiapril (10 mg/day) was chosen
KASKI ET AL .
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on the basis of recently reported observations (15) in patients
with transient myocardial ischemia . All antianginal medica-
tion was discontinued X72 h before the study, with the
exception of sublingual nitrates, which were allowed for
relief of anginal attacks
. After appropriate washout of pre-
vious medications, patients were randomized to receive
either enalapril or placebo for 2 weeks . After a 1-week
washout period, patients were crossed over to receive either
enalapril or placebo for another 2 weeks .
Patients were assessed by symptom-limited exercise tests
(modified Bruce protocol) . These tests were carried out 2 h
after drug administration on the last day of each treatment
period .
Exercise testing
. Before the exercise test and after the
ECG electrodes were placed on the chest according to a
standardized technique, patients were asked to rest in the
sitting position for 30 min
. They were then invited to stand
up, and rest heart rate, blood pressure and rate pressure
product (heart rate x systolic blood pressure expressed in
beats/min x mm Hg) were measured after 2 to 3 min in the
standing position . All patients underwent exercise testing
under standardized conditions . The modified Bruce protocol
was used in all tests ; the end points were a 2-mm depression
of the ST segment, progressive angina or fatigue . Twelve-
lead ECG and blood pressure measurements were obtained
during the control period, at 1-min intervals during exercise
and for 6 min during recovery . After signal averaging, the
level of the ST segment 80 ms after the J point was measured
in all 12 leads with use of a computer-assisted system (CASE
Marquette 12, Marquette Electronics Inc .) . The lead show-
ing the most ST segment depression was selected for analy-
sis. In patients with positive test results, the duration of
exercise, heart rate and rate-pressure product were mea-
sured at 1-nim depression of the ST segment and at peak
exercise ; in those with negative test results, the duration of
exercise, heart rate and rate-pressure product were mea-
sured at peak exercise only .
Statistical analysis . All data were analyzed without
knowledge of the patients' treatment . Rest pre-exercise
heart rate, blood pressure and rate-pressure product were
measured in the upright position in every patient . The
following exercise variables were also measured : total exer-
cise time, time to I mm of ST segment depression, heart
rate, systolic blood pressure and rate-pressure product at
peak exercise and 1 mm of ST segment depression . The
magnitude of ST segment depression at peak exercise was
also assessed. Data are presented as mean value ± SD .
Student t tests were carried out to compare placebo versus
enalapril results as appropriate . AA p value < 0
.05 was
considered significant .
Results
All 10 patients completed the study uneventfully and no
side effects were observed during the relatively short treat-
ment period . Routine hematologic and biochemical variables
654
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Figure 1. Hemodynamic variables . Bargraphs showing mean values
±SD for heart rate (HR), systolic blood pressure (SBP) and rate-
pressure product (double product of the heart rate and systolic blood
pressure [RPPI) during treatment with placebo (solid bars) and the
angiotensin-converting enzyme inhibitor enalapril (open bars) . At
rest (A) . During treatment with enalapril, systolic blood pressure
and the rate-pressure product significantly decreased compared with
values during placebo treatment . However, reflex tachycardia was
not observed. At peak exercise (B) and at I mm of ST segment
depression (C), no significant differences in hemodynamic variables
were observed when placebo and enalapril treatment periods were
compared.
remained unchanged during the study in all patients . Body
weight did not change significantly when placebo and enal-
april treatment periods were compared .
Pre-exerdse rtemodynamic variables . Systolic blood pres-
sure at rest was significantly lower with enalapril than with
placebo (125 ± 12 vs . 133 ± 9 mm Hg, p = 0 .009) (Fig . IA) .
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How.;-er, !art rate was not significantly different with
ei alapril (b I ± 10 vs . 95 ± 15 beats/min, p = NS) . As a result
of Ns, the rate-pressure product was also significantly lower
with enalapril than with placebo (Fig . IA) .
Exercise hemodynamics. Systolic blood pressure was not
significantly different at peak exercise during enalapril and
placebo treatment (177 ± 26 and 183 ± 23 mm Hg, respec-
tively, p = NS) . Heart rate and rate-pressure product were
also similar during the two treatment periods (Fig . 1B) .
Similar to results at peak exercise, heart rate, blood
pressure and the rate-pressure product at 1 mm of ST
segment depression were not significantly diTerent during
placebo and enalapril treatment (Fig. 1Q.
Exercise time. Despite similar values for rate-pressure
product in the two treatment Nriods, exercise time was
significantly longer with enalapril than with placebo (779 ±
141 vs. 690 ± 148 s, respectively, p = 0 .006) (Fig. 2). Time
to 1 mm of ST segment depression was also significantly
prolonged by enalapril (690 ± 204 vs . 485 ± 241 s, p = 0 .007)
(Fig. 2). With enalapril, three patients had a 2t20% longer
peak exercise time and six had a atM increase in time to
I mm of ST segment depression (Fig. 2) .
ST segment depression . On average, the magnitude of ST
segment depression was significantly reduced during treat-
ment with the angiotensin-converting enzyme inhibitor enal-
april compared with the value recorded during placebo
treatment (Fig . 3). All patients had a positive exercise test
result (with angina) during placebo treatment . With enala-
pril, four patients had a negative test response (< I mm of ST
segment depression and no angina) and two others had a
borderline positive test response without angina . During
treatment with enalapril, 9 of the 10 patients consistently
improved their exercise capacity and had <1 mm of ST
segment depression (4 patients) or ST segment depression of
lesser magnitude than that during exercise with placebo
treatment (Fig . 3) .
Discussion
The results of our study showed that the angiotensin-
converting enzyme inhibitor enalapril improves exercise-
induced angina and ST segment depression in patients with
syndrome X and microvascular angina . During treatment
with enalapril, 40% of the patients had a negative exercise
test result and, in the group as a whole, exercise duration
and time to 1 mm of ST segment depression were signifi-
cantly prolonged by enalapril compared with placebo . When
individual results are considered, the majority of patients
increased the time to 1 mm of ST segment depression by
2t20% while taking enalapril . The magnitude of ST segment
depression at peak exercise was also lessened by the admin-
istration of enalapril . Patient compliance was good and all
patients completed the study without observed side effects
during treatment with the angiotensin-converting enzyme
inhibitor .
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Figure 2. Exercise time. Exercise time at both I mm of ST segment
depression (left panel) and at peak exercise (right panel) in individual
patients with syndrome X during placebo and enalapril therapy .
While receiving enalapril, three patients had a >_20% increase in
exercise time and six had a L-20 decrease in time to I mm of ST
segment depression compared with values during the placebo pe-
riod . Thick lines indicate patients who did not reach I mm of ST
segment depression (negative exercise test result) .
Mechanisms potentially responsible for decreasing exer-
cise-induced ischernia. There are different mechanisms by
which angiotensin-converting enzyme inhibitors can lessen
myocardial ischemia in patients with angina . A reduction of
the rate-pressure product (22), which in turn results in a
reduced cardiac work, is one of these . In our patients,
enalapril provoked a decrease in rest blood pressure (with-
out reflex tachycardia), thus reducing the rest rate-pressure
product, as previously observed in other studies (23) . How-
ever, peak exercise heart rate and rate-pressure product
were not significantly different when placebo and enalapril
were compared. The decrease of myocardial ischemia in
response to enalapril therefore occurred in the presence of a
rate-pressure product at peak exercise that was similar to
that observed while the patients exercised during treatment
with placebo . This finding suggests that the beneficial effect
of enalapril observed in our study could have resulted from
a direct modulation of coronary microvascular artery tone
by the angiotensin-converting enzyme inhibitor . The role of
the renin-angiotensin system on modulation of coronary
artery blood flow has not been thoroughly investigated
despite the well known potency of angiotensin II as a
coronary vasoconstrictor . The emerging concept that angio-
tenMn is produced locally at tissue sites has important
implications, as local angiotensin concentrations may ex-
ceed those of plasma levels and may play an important role
in the tonic control of vascular resistance (24-26) . There is
evidence in humans and experimental models that coronary
KASKI ET AL
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Figure 3 . ST segment depression at peak exercise . Individual re-
sults of the magnitude of ST segment depression during placebo and
enalapril therapy . All patients had a positive exercise test result
(2! 1 aim of ST segment depression) during placebo treatment . With
enalapril, four patients had a negative exercise test response . Nine
of the 10 study patients showed a reduced magnitude of peak
exercise ST segment depression during enalapril therapy compared
with that during placebo therapy .
vascular resistance is increased by angiotensin 11 (27) . In
different models of myocardial ischemia, endogenous angio-
tensin 11 exerts intense coronary arteriolar constriction,
which can be prevented by pretreatment with angiotensin-
converting enzyme inhibitors (28) . However, the nature of
myocardial ischemia may differ between syndrome X and
other coronary syndromes . It has been shown that angioten-
sin-converting enzyme inhibition attenuates sympathetic
coronary vasoconstriction in patients with coronary artery
disease (29) . The mechanism appears to be the removal of
the facilitating influence of angiotensin II on sympathetic
modulation of coronary vasomotor tone (29) . Angiotensin-
converting enzyme inhibitors have also been shown to
increase coronary blood flow in patients with heart failure
associated with dilated cardiomyopathy or ischemic heart
disease (30) . Enalapril (or more appropriately, its active
metabolite enalaprilat) is an antagonist of angiotensin 11 in
isolated coronary arteries (31) and antagonizes the coronary
vasoconstrictor effect of angiotensin II (32) . These observa-
tions suggest that the renin-angiotensin system, when stim-
ulated, can exert a direct vasoconstrictor effect on vascular
tone and that angiotensin-converting enzyme inhibitors may
play a beneficial role .
Increased sympathetic drive in patients with syndrome X .
An increased sympathetic drive has been suggested to play a
role in the genesis of angina in patients with syndrome X
(33,34) and an interaction between the sympathetic nervous
system and the renin-angiotensin system has been docu-
mented (35) . Facilitation of sympathetic nerve influences in
the heart by angiotensin 11 contributes to its inotropic action
and possibly to its effects on coronary blood flow (35) .
Ganten (35) reported that the effects of sympathetic stimu-
lation on isolated perfused heart preparations were signifi-
cantly reduced by pretreatment with angiotensin-converting
656
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enzyme inhibitors . More recently, Perondi et al. (29) ob-
served that treatment with captopril resulted in the attenua-
tion of sympathetic coronary artery vasoconstriction in
patients with atheromatous coronary artery disease. These
findings are of particular relevance in syndrome X, at least in
the subgroup of patients in whom an increased sympathetic
drive plays a pathogenic role. It is also conceivable that
attenuating the effects of the sympathetic nervous system on
cardiac contractility could have contributed to the beneficial
effect of angiotensin-converting enzyme inhibition that we
observed in our patients with microvascular angina (13,14) .
Experimental evidence (31) suggests that in addition to
antagonizing the coronary arteriolar constrictor action of
angiotensin II, angiotensin-converting enzyme inhibitors
also have cardioprotective properties . Because these agents
can prevent bradykinin breakdown by inhibition of kininase
II and can stimulate prostaglandin production, it has been
postulated that at least some of the cardiac effects of
angiotensin-converting enzyme inhibition depend on these
properties (25,35). However, no conclusive evidence is
available that the effects of angiotensin-converting enzyme
inhibition are fully mediated by prostaglandins and bradyki-
nin (36) .
C ns. The results of our study suggest that angio-
tensin-converting enzyme inhibition lessens exercise-
induced angina and ST segment depression in patients with
syndrome X who have a reduced coronary blood flow
reserve. The mechanism by which angiotensin-converting
enzyme inhibition exerts its beneficial effect in patients with
microvascular angina is not yet known, but modulation of
coronary tone at the microcirculation level may be a poten-
tial mechanism . Our findings may help to improve patient
management .
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